Michael Skinner

This inventor holds 9 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents. Top assignees: Currax Pharmaceuticals LLC, Pernix Sleep, Inc., Somaxon Pharmaceuticals, Inc.. Active years: 2011-2021.

USPTO Granted Patents = 9 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 7.4

ph-index = 2

Forward Citations = 22(Granted Patents)

Company Filing History:

5 out of 13

Currax Pharmaceuticals LLC

Somaxon Pharmaceuticals, Inc.

patent

Years Active: 2011-2021

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11110074 - Methods of improving the pharmacokinetics of doxepin (2021-09-07),

2. 11096920 - Low-dose doxepin formulations and methods of making and using the same (2021-08-24),

3. 11013712 - Methods of treating insomnia using a combination therapy of low-dose doxepin and zolpidem (2021-05-25),

4. 10653660 - Methods of improving the pharmacokinetics of doxepin (2020-05-19),

5. 10548871 - Low-dose doxepin formulations and methods of making and using the same (2020-02-04),

6. 9907780 - Low-dose doxepin formulations and methods of making and using the same (2018-03-06),

7. 9572814 - Methods of improving the pharmacokinetics of doxepin (2017-02-21),

8. 9532971 - Low-dose doxepin formulations and methods of making and using the same (2017-01-03),

9. 7915307 - Methods of improving the pharmacokinetics of doxepin (2011-03-29),

Title: Michael Skinner: Innovator in Pharmacokinetics

Introduction

Michael Skinner is a prominent inventor based in San Diego, California. He has made significant contributions to the field of pharmacokinetics, particularly in the development of formulations that enhance the efficacy of medications. With a total of nine patents to his name, Skinner's work has had a notable impact on pharmaceutical science.

Latest Patents

Among his latest patents, Skinner has developed methods for improving the pharmacokinetics of doxepin, a medication commonly used for sleep disorders. His patent titled "Methods of improving the pharmacokinetics of doxepin in a patient" focuses on optimizing the drug's effectiveness. Additionally, he has created low-dose doxepin formulations, which are detailed in his patent "Low-dose doxepin formulations and methods of making and using the same." This invention relates to oral pharmaceutical formulations designed to promote sleep, showcasing his commitment to enhancing patient care.

Career Highlights

Throughout his career, Michael Skinner has worked with notable companies in the pharmaceutical industry. He has been associated with Currax Pharmaceuticals LLC and Pernix Sleep, Inc., where he has contributed his expertise in drug formulation and development. His work has been instrumental in advancing the understanding and application of doxepin in clinical settings.

Collaborations

Skinner has collaborated with esteemed colleagues, including Philip Jochelson and Robert Mansbach. These partnerships have fostered innovation and have been crucial in the development of his patented technologies.

Conclusion

Michael Skinner's contributions to pharmacokinetics and his innovative approaches to drug formulation have established him as a key figure in the pharmaceutical industry. His work continues to influence the development of effective treatments for sleep disorders.